George Simeon, Curevo Vaccine CEO

A small Seat­tle biotech wants to take on Glax­o­SmithK­line's emerg­ing Shin­grix block­buster. RA Cap­i­tal is on board

Glax­o­SmithK­line’s Shin­grix has quick­ly be­come one of the com­pa­ny’s best-sell­ing prod­ucts since first win­ning FDA ap­proval in 2017. But a new biotech be­lieves it can do bet­ter — and RA Cap­i­tal is lis­ten­ing.

Cure­vo Vac­cine, a Seat­tle-based com­pa­ny, de­buted a $60 mil­lion Se­ries A on Thurs­day led by the promi­nent life sci­ences VC, aim­ing to fund a Phase IIb study for its shin­gles vac­cine can­di­date. The pro­gram, known as CRV-101, will be mea­sured against Shin­grix as the con­trol and pits the two shots head-to-head.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.